Cytek Biosciences (CTKB) has announced preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Total revenue for the full year 2025 is expected to be approximately $201 million, with fourth-quarter revenue projected at approximately $62 million, showing an 8% growth compared to the same period in 2024. Cytek plans to report financial results for the fourth quarter and provide 2026 financial guidance during its upcoming earnings call expected to be held near the end of February 2026. In pre-market trading on NasdaqGS, Cytek Biosciences shares are up 9.7% to $5.98. Visit rttnews.com for more earnings news and calendar updates.

Read more at Nasdaq: Cytek Biosciences Preliminary Q4 Revenue Up 8%